Court in France wants Mylan to pay Ipsen $24 million

PARIS — A court in France has ordered generic drug maker Mylan to pay French drug maker Ipsen $24 million for allegedly misleading marketing of a drug, according to published reports.

Bloomberg reported that Mylan had allegedly marketed the drug Vitalogink as a generic version of Ipsen’s Tanakan rather than as a “therapeutic equivalent.” Both drugs are derived from ginkgo biloba and are used to improve memory.

Mylan has said it will appeal the decision, Bloomberg reported.

Login or Register to post a comment.